ProMIS Neurosciences Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
8
- Stock Symbol
-
PMN
- Investments
-
2
- Share Price
-
$0.64
- (As of Thursday Closing)
ProMIS Neurosciences General Information
Description
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
Contact Information
Website
www.promisneurosciences.comCorporate Office
- 1920 Yonge Street
- Suite 200
- Toronto, Ontario M4S 3E2
- Canada
Corporate Office
- 1920 Yonge Street
- Suite 200
- Toronto, Ontario M4S 3E2
- Canada
ProMIS Neurosciences Timeline
ProMIS Neurosciences Stock Performance
As of 17-Apr-2025, ProMIS Neurosciences’s stock price is $0.64. Its current market cap is $20.8M with 32.7M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.64 | $0.61 | $0.51 - $2.37 | $20.8M | 32.7M | 40.5K | $0.11 |
ProMIS Neurosciences Financials Summary
As of 31-Dec-2024, ProMIS Neurosciences has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 9,414 | 9,414 | 5,095 | 34,656 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | 2,856 | 2,856 | (12,990) | (17,769) |
| Net Income | 2,779 | 2,779 | (13,212) | (18,062) |
| Total Assets | 18,911 | 18,911 | 13,619 | 6,925 |
| Total Debt | 6 | 6 | 94 | 1,859 |
ProMIS Neurosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ProMIS Neurosciences Comparisons
Industry
Financing
Details
ProMIS Neurosciences Competitors (40)
One of ProMIS Neurosciences’s 40 competitors is Anavex Life Sciences, a Corporation company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Anavex Life Sciences | Corporation | New York, NY | ||||
| Quince Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Neurogene | Formerly VC-backed | New York, NY | ||||
| Alzheon | Venture Capital-Backed | Framingham, MA | ||||
| Compass Therapeutics | Formerly VC-backed | Boston, MA |
ProMIS Neurosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ProMIS Neurosciences Patents
ProMIS Neurosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3176840-A1 | Single chain antibodies and intrabodies to misfolded tdp-43 and methods of use | Pending | 29-Apr-2020 | ||
| EP-4143322-A1 | Single chain antibodies and intrabodies to misfolded tdp-43 and methods of use | Pending | 29-Apr-2020 | ||
| AU-2021265165-A1 | Single chain antibodies and intrabodies to misfolded tdp-43 and methods of use | Pending | 29-Apr-2020 | ||
| JP-2023523066-A | Single-chain antibodies and intrabodies against misfolded tdp-43 and methods of use | Pending | 29-Apr-2020 | ||
| US-20230174630-A1 | Single chain antibodies and intrabodies to misfolded tdp-43 and methods of use | Pending | 29-Apr-2020 | C07K16/18 |
ProMIS Neurosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ProMIS Neurosciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ProMIS Neurosciences Investments & Acquisitions (2)
ProMIS Neurosciences’s most recent deal was a Joint Venture with Developer of Tests for Detection of Alzheimer's Disease (ProMIS Neurosciences / BC Neuroimmunology). The deal was made on 09-Jul-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Developer of Tests for Detection of Alzheimer's Disease (ProMIS Neurosciences / BC Neuroimmunology) | 09-Jul-2020 | Joint Venture | Diagnostic Equipment | ||
| Amorfix Life Sciences | 08-Jul-2015 | Merger/Acquisition | Therapeutic Devices |
ProMIS Neurosciences FAQs
-
When was ProMIS Neurosciences founded?
ProMIS Neurosciences was founded in 2004.
-
Where is ProMIS Neurosciences headquartered?
ProMIS Neurosciences is headquartered in Toronto, Canada.
-
What is the size of ProMIS Neurosciences?
ProMIS Neurosciences has 8 total employees.
-
What industry is ProMIS Neurosciences in?
ProMIS Neurosciences’s primary industry is Drug Discovery.
-
Is ProMIS Neurosciences a private or public company?
ProMIS Neurosciences is a Public company.
-
What is ProMIS Neurosciences’s stock symbol?
The ticker symbol for ProMIS Neurosciences is PMN.
-
What is the current stock price of ProMIS Neurosciences?
As of 17-Apr-2025 the stock price of ProMIS Neurosciences is $0.64.
-
What is the current market cap of ProMIS Neurosciences?
The current market capitalization of ProMIS Neurosciences is $20.8M.
-
Who are ProMIS Neurosciences’s competitors?
Anavex Life Sciences, Quince Therapeutics, Neurogene, Alzheon, and Compass Therapeutics are some of the 40 competitors of ProMIS Neurosciences.
-
What is ProMIS Neurosciences’s annual earnings per share (EPS)?
ProMIS Neurosciences’s EPS for 12 months was $0.11.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
